Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $160
Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.
Follow the latest Gilead Sciences Inc. (GILD) news and market headlines alongside the live GILD price. Stay informed on what's moving GILD.
Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.
Invesco Pharmaceuticals ETF (PJP) delivered 36.1% one-year returns with concentrated pharma exposure, significantly outperforming Simplify Health Care ETF (PINK) at 22.7%. PINK offers lower expenses, broader healthcare diversification, and donates profits to breast cancer research, while PJP provides 20+ years of track record but carries sector concentration risk.
The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.
State Street's XPH (SPDR S&P Pharmaceuticals ETF) is recommended over Invesco's PBE (Biotechnology & Genome ETF) for long-term investors due to its lower expense ratio (0.35% vs 0.59%), broader diversification with 61 holdings, lower beta, and better recent 1-year performance (38.6% vs 33.2%). While PBE offers a higher dividend yield (1.3% vs 0.4%), XPH's exposure to pharmaceutical acquisitions and lower costs make it more suitable for most long-term investors.
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
Zacks Research Daily features analysis of 16 major stocks on November 12, 2026. Home Depot benefits from digital investments and Pro initiatives but faces subdued discretionary projects. Gilead outperforms with strong HIV franchise but faces intensifying competition. TotalEnergies underperforms due to geopolitical risks despite diversified portfolio. Key Tronic and iPower face significant challenges with declining performance. Additional coverage includes Marathon Petroleum, Bank of New York Mellon, and Suncor Energy.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
Gilead Sciences reported strong momentum in its HIV business, with flagship drug Biktarvy commanding 53% U.S. market share and injectable PrEP therapy Yeztugo emerging as a key growth driver with $305 million in quarterly sales. The company raised its 2026 HIV sales growth outlook to 12%, supported by strong performances from Biktarvy, Descovy, and Yeztugo. However, aggressive dealmaking and integration costs are pressuring near-term profitability.
AbbVie raised its 2026 revenue guidance to $67.8 billion for the third time this year, driven by strong performance from Skyrizi and Rinvoq, which are offsetting Humira's patent-driven decline. The company's neuroscience portfolio, including Vyalev and migraine drugs, is also contributing to growth. However, aesthetics sales remain soft and oncology growth is subdued. AbbVie maintains a Zacks Rank #3 (Hold) rating with solid long-term prospects.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to GILD, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.